Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK.
Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, AV Hill Building, Oxford Road, Manchester M13 9PT, UK.
Cell Chem Biol. 2017 Nov 16;24(11):1321-1335.e5. doi: 10.1016/j.chembiol.2017.08.011. Epub 2017 Sep 21.
NLRP3 is a receptor important for host responses to infection, yet is also known to contribute to devastating diseases such as Alzheimer's disease, diabetes, atherosclerosis, and others, making inhibitors for NLRP3 sought after. One of the inhibitors currently in use is 2-aminoethoxy diphenylborinate (2APB). Unfortunately, in addition to inhibiting NLRP3, 2APB also displays non-selective effects on cellular Ca homeostasis. Here, we use 2APB as a chemical scaffold to build a series of inhibitors, the NBC series, which inhibit the NLRP3 inflammasome in vitro and in vivo without affecting Ca homeostasis. The core chemical insight of this work is that the oxazaborine ring is a critical feature of the NBC series, and the main biological insight the use of NBC inhibitors led to was that NLRP3 inflammasome activation was independent of Ca. The NBC compounds represent useful tools to dissect NLRP3 function, and may lead to oxazaborine ring-containing therapeutics.
NLRP3 是宿主对感染反应的重要受体,但也已知其会导致阿尔茨海默病、糖尿病、动脉粥样硬化等破坏性疾病,因此 NLRP3 的抑制剂备受关注。目前正在使用的抑制剂之一是 2-氨基乙氧基二苯硼酸盐(2APB)。不幸的是,除了抑制 NLRP3 之外,2APB 还对细胞钙稳态表现出非选择性作用。在这里,我们使用 2APB 作为化学支架构建了一系列抑制剂 NBC 系列,这些抑制剂在不影响钙稳态的情况下在体外和体内抑制 NLRP3 炎性小体。这项工作的核心化学见解是,噁嗪硼环是 NBC 系列的关键特征,使用 NBC 抑制剂的主要生物学见解是 NLRP3 炎性小体的激活不依赖于 Ca。NBC 化合物是剖析 NLRP3 功能的有用工具,并且可能导致含有噁嗪硼环的治疗方法。
Cell Chem Biol. 2017-9-21
Bioorg Med Chem. 2017-11-28
Arterioscler Thromb Vasc Biol. 2017-8
Naunyn Schmiedebergs Arch Pharmacol. 2025-7-23
Inflammopharmacology. 2025-2
Front Pharmacol. 2024-2-8
Curr Med Chem. 2024
Curr Pharm Biotechnol. 2024
Cell Death Dis. 2023-12-21
Eur J Med Chem Rep. 2023-4
J Med Chem. 2015-10-12
Nat Immunol. 2015-3